International Plasma Protein Congress (IPPC 2025)

The IPPC 2025 program spans two days of expert-led sessions and discussions. Key scientific sessions and topics include:

Patient-Led Conversation on PDMPs & Progress: A discussion with patients and advocates reflecting on two decades of progress in disease diagnosis, access to PDMPs, policy changes, and future patient needs.
 
Critical Medicines – European Strategies for Preventing Shortages and Securing Supply: Examination of the EU’s latest efforts to strengthen medical supply chains and prevent disruptions. This session covers new initiatives (e.g. Pharmaceutical Legislation, Critical Medicines Act, European Shortages Monitoring Platform) aimed at improving the resilience of healthcare systems and plasma-derived medicines supply.

Global Perspectives on Improving Patient Access: Challenges that limit patient access to plasma-derived medicines outside Europe and the U.S., and innovative solutions being implemented in diverse regions to expand access.

Innovation: What’s Next for PDMPs?: Emerging innovations in plasma protein therapeutics research and development. Attendees learn about ongoing work to develop novel therapies and new evidence-based indications for approved treatmen

Methodologies in Donor Health and Safety Research: How real-world data is used to generate evidence for improving plasma donor health and safety. This session highlights current research methodologies and findings that inform donor safety practices.

Building a Resilient Supply of Plasma for Fractionation: Strategies and lessons for creating a sustainable, resilient global plasma supply chain to meet growing patient demand. Experts discuss the value of public-private collection models and the impact of implementing the EU SoHO (Substances of Human Origin) regulation.

Ensuring Access – The Role of Market Policies for PDMPS: The impact of market policies (such as mandatory stockpiling and reimbursement rules) on plasma therapies and patients. This session offers policy recommendations and argues for shifting from on-size-fits-all policies to more patient-centric approaches.